Identification of an interactome network between lncRNAs and miRNAs in thyroid cancer reveals SPTY2D1-AS1 as a new tumor suppressor

• Published in: Scientific reports Vol. 12; no. 1; pp. 7706 - 13
• Main Authors: Ramírez-Moya, Julia, Wert-Lamas, León, Acuña-Ruíz, Adrián, Fletcher, Alice, Wert-Carvajal, Carlos, McCabe, Christopher J., Santisteban, Pilar, Riesco-Eizaguirre, Garcilaso
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.05.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/67/1459; 631/67/69; 692/163; Gene regulation; Humanities and Social Sciences; Malignancy; miRNA; multidisciplinary; Neuroendocrine tumors; Non-coding RNA; Nucleotides; Post-transcription; Science; Science (multidisciplinary); Therapeutic targets; Thyroid; Thyroid cancer; Tumor suppressor genes; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-11725-4

Thyroid cancer is the most common primary endocrine malignancy in adults and its incidence is rapidly increasing. Long non-coding RNAs (lncRNAs), generally defined as RNA molecules longer than 200 nucleotides with no protein-encoding capacity, are highly tissue-specific molecules that serve important roles in gene regulation through a variety of different mechanisms, including acting as competing endogenous RNAs (ceRNAs) that ‘sponge’ microRNAs (miRNAs). In the present study, using an integrated approach through RNA-sequencing of paired thyroid tumor and non-tumor samples, we have identified an interactome network between lncRNAs and miRNAs and examined the functional consequences in vitro and in vivo of one of such interactions. We have identified a likely operative post-transcriptional regulatory network in which the downregulated lncRNA, SPTY2D1-AS1, is predicted to target the most abundant and upregulated miRNAs in thyroid cancer, particularly miR-221, a well-known oncomiRNA in cancer. Indeed, SPTY2D1-AS1 functions as a potent tumor suppressor in vitro and in vivo, it is downregulated in the most advanced stages of human thyroid cancer, and it seems to block the processing of the primary form of miR-221. Overall, our results link SPTY2D1-AS1 to thyroid cancer progression and highlight the potential use of this lncRNA as a therapeutic target of thyroid cancer.